In a significant stride towards enhancing cancer care in Spain, MSD has joined as a financing member the All.Can Spain platform, the Spanish chapter of All.Can International, together with Bristol-Myers Squibb and Amgen. This incorporation comes at a time of maximum urgency, as in 2023 tumors became the leading cause of death in Spain[1], accounting for 26.6% of all deaths, surpassing for the first time deaths caused by diseases of the circulatory system.
With MSD’s addition, All.Can Spain continues to expand its network, strengthening the multidisciplinary approach needed to combat the complex challenge of cancer. This new membership will empower the All.Can Spain Scientific Committee to further their efforts in identifying and addressing inefficiencies in cancer care, ensuring the highest quality treatment and a better experience for cancer patients.
For more information on the ongoing efforts of All.Can Spain, visit our website.
[1] Estadística de Defunciones según la Causa de Muerte. https://www.ine.es/dyngs/Prensa/pEDCM2023.htm